Medicenna Therapeutics

Company snapshot

Medicenna is a clinical-stage immunotherapy company pioneering next-generation Superkines - engineered cytokines designed to overcome the limitations of other cytokines and unlock new treatment opportunities in oncology, immunology, and inflammatory diseases. Our mission is to develop life-changing immunotherapies that transform people's lives and deliver the best possible patient outcomes. Our Su

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Medicenna Therapeutics. Not investment advice.

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  Daiichi Sankyo US

  TA overlap score 31.6

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  Eikon Therapeutics

  TA overlap score 23

• Peer + 0 momentum

  Multitude Therapeutics

  TA overlap score 20.4

Recent activity

Latest pipeline, patent, and corporate events for Medicenna Therapeutics.

1. Jun 8, 2026 Clinical update

   MDNA11-01 — Phase 2

2. May 23, 2026 Clinical update

   MDNA11 — Phase 2

3. May 23, 2026 Clinical update

   MDNA55 — Phase 2

4. Sep 2, 2025 Patent grant

   Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof

5. Jun 24, 2025 Patent grant

   IL-2 superagonists in combination with anti-PD-1 antibodies

View all clinical trial activity →

• What is Medicenna Therapeutics?

  Medicenna Therapeutics is a pharma organization headquartered in Toronto, CA. It trades on NYSE under ticker MDNAF. Primary therapeutic focus areas include Advanced Solid Tumors, Advanced Solid Tumor, Glioblastoma. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), an

• Is Medicenna Therapeutics publicly traded?

  Yes. Medicenna Therapeutics is listed with ticker MDNAF on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Medicenna Therapeutics develop or market?

  We link 3 drug profile(s) where Medicenna Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/medicenna-therapeutics#company-drugs.

• What are the latest developments for Medicenna Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Medicenna Therapeutics focus on?

  Medicenna Therapeutics focuses on Advanced Solid Tumors, Advanced Solid Tumor, Glioblastoma based on our analysis of their pipeline programs and drug development activities.